BindingDB logo
myBDB logout

37 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
25782055 9 Discovery of a Cyclic Boronic Acid-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.EBI Rempex Pharmaceuticals, Inc.
23719288 41 Discovery of novel series of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones as human chymase inhibitors using structure-based drug design.EBI Asubio Pharma Co., Ltd
23659209 30 Discovery of potent, selective chymase inhibitors via fragment linking strategies.EBI Boehringer Ingelheim Pharmaceuticals Inc.
16644215 52 Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.EBI Celera Genomics
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
18053726 364 Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI Johnson& Johnson Pharmaceutical Research& Development
18247547 6 Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.EBI Cephalon, Inc.
11312928 62 Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic difluoromethylene ketones as novel inhibitors of human chymase.EBI Welfide Corporation
11312927 64 Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic alpha-keto heterocycles as novel inhibitors of human chymase.EBI Welfide Corporation
22192588 9 Structure-based library design and the discovery of a potent and selective mast cellß-tryptase inhibitor as an oral therapeutic agent.EBI Sanofi Pharmaceuticals
21733690 40 Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) region.EBI Boehringer Ingelheim Pharmaceuticals Inc.
20970895 4 2-Azetidinone--a new profile of various pharmacological activities.EBI Barkatullah University
19841155 29 MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.EBI Merck Research Laboratories
20102150 35 Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.EBI Johnson& Johnson Pharmaceutical Research and Development
19908842 84 Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.EBI National Human Genome Research Institute
17434735 34 Development of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones as orally active human chymase inhibitors.EBI Daiichi Asubio Pharma Co., Ltd
17419055 30 Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5-diones as a novel scaffold for human chymase inhibitors.EBI Daiichi Asubio Pharma Co., Ltd
17361995 31 Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.EBI Johnson & Johnson Pharmaceutical Research and Development
16725321 13 Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.EBI Celera Genomics
14592513 24 Structure-activity relationship of benzo[b]thiophene-2-sulfonamide derivatives as novel human chymase inhibitors.EBI Toa Eiyo Ltd.
12467610 1 Identification of a stable chymase inhibitor using a pharmacophore-Based database search.EBI TOA EIYO Ltd.
11425540 6 Total synthesis of human chymase inhibitor methyllinderone and structure--activity relationships of its derivatives.EBI Shionogi & Co., Ltd.
11425539 23 Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones.EBI Shionogi & Co., Ltd.
11078188 20 1-Oxacephem-based human chymase inhibitors: discovery of stable inhibitors in human plasma.EBI Shionogi & Co., Ltd
11078187 36 Synthesis and structure-activity relationships of a new class of 1-oxacephem-based human chymase inhibitors.EBI Shionogi & Co., Ltd
10698435 150 Structure-activity relationship studies of chloromethyl ketone derivatives for selective human chymase inhibitors.EBI Kyoto Pharmaceutical University
10091694 90 Symmetrical anhydride-type serine protease inhibitors: structure-activity relationship studies of human chymase inhibitors.EBI Nippon Steel Corporation
9925737 57 N-[2,2-dimethyl-3-(N-(4-cyanobenzoyl)amino)nonanoyl]-L-phenylalanine ethyl ester as a stable ester-type inhibitor of chymotrypsin-like serine proteases: structural requirements for potent inhibition of alpha-chymotrypsin.EBI Nippon Steel Corporation
9871512 20 Peptidyl human heart chymase inhibitors. 2. Discovery of highly selective difluoromethylene ketone derivatives with Glu at P3 site.EBI Green Cross Research Laboratories
9871511 54 Peptidyl human heart chymase inhibitors. 1. Synthesis and inhibitory activity of difluoromethylene ketone derivatives bearing P' binding subsites.EBI Green Cross Research Laboratories
9216834 153 Substituted 3-(phenylsulfonyl)-1-phenylimidazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase.EBI Suntory Ltd.
15449728 11 Design and synthesis of indole and tetrahydroisoquinoline hydantoin derivatives as human chymase inhibitors.BDB Université de Tours
9468142 60 Design of potent selective zinc-mediated serine protease inhibitors.BDB Arris